Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients

SHANGHAI, March 19, 2024 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, announced today that the Singapore Health…